Open Label Study of Subcutaneous Homoharringtonine in Patients with Advanced CML Study Type: Interventional

December 31, 2009

This study will be evaluating the efficacy of subcutaneous homoharringtonine (CGX-635) in the treatment of patients with CML who have failed or are intolerant to tyrosine kinase inhibitor therapy.

Age/Sex Requirements: 18 years+

Sponsor: ChemGenex Pharmaceuticals

Purpose: This study will be evaluating the efficacy of subcutaneous homoharringtonine (CGX-635) in the treatment of patients with CML who have failed or are intolerant to tyrosine kinase inhibitor therapy. The focus of the study will be clinical response, with secondary measures including the degree of hematologic response, time to response, time to progression, and patient survival rate.

Click here to access this third-party website.